3-Hydroxybutyrate Prevents Pulmonary Vein Arrhythmogenesis by Regulating Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Oxidative Stress
Pharmacology · 20.03.2026 · 1-16
DOI: 10.1159/000551614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, online erschienen am 20.03.2026. Verfasst von Chye-Gen Chin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Calcium-Calmodulin-Dependent Protein Kinase Type 2, Oxidative Stress, Pulmonary Veins, 3-Hydroxybutyric Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Introduction
Atrial fibrillation is the most common sustained cardiac arrhythmia, primarily caused by arrhythmogenic activity within the pulmonary veins (PVs). Enhanced ketone body utilization can prevent heart failure by reducing inflammation and oxidative stress, factors crucial for atrial fibrillation pathogenesis. However, the role of ketone bodies in PV arrhythmogenesis remains unclear. This study investigated the effect of 3-hydroxybutyrate (3-OHB), the most abundant ketone body, on PV arrhythmogenesis and explored the underlying mechanisms.
Methods
Using conventional microelectrodes and the patch-clamp technique, we analyzed electrophysiological characteristics and ionic currents in isolated rabbit PV tissues and single PV cardiomyocytes.
Results
The effects of 3-OHB (10 mm) on reactive oxygen species (ROS) production, calcium homeostasis, and phosphorylated calcium/calmodulin-dependent protein kinase II (CaMKII) expression were analyzed through confocal microscopy and Western blotting. The results indicated that 3-OHB dose-dependently reduced PV spontaneous activity, contractility, and diastolic tension. However, these effects were blocked by KN93 and AIP, a CaMKII inhibitor. Moreover, 3-OHB reduced late sodium and L-type calcium currents in PV cardiomyocytes; these effects were blocked by KN93 and AIP. Furthermore, 3-OHB reduced cytosolic ROS levels and phosphorylated CaMKII expression.
Conclusion
3-OHB prevents PV arrhythmogenesis by modulating ionic currents, reducing ROS production, and regulating CaMKII signaling. Thus, 3-OHB holds promise as an antiarrhythmic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Biomedical Engineering, National Defense Medical Center, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei City, Taiwan.
- Cardiac Electrophysiology and Pacing Laboratory, Division of Cardiovascular Medicine, Makiminato Central Hospital, Okinawa, Japan.
Zitieren
APA
Chin, C. G., Lin, F. J., Chen, Y. C., Lin, Y. K., Lu, Y. Y., Higa, S., Kao, Y. H., Chen, S. A., & Chen, Y. J. (2026). 3-Hydroxybutyrate Prevents Pulmonary Vein Arrhythmogenesis by Regulating Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Oxidative Stress. Pharmacology, 1-16. https://doi.org/10.1159/000551614
Vancouver
Chin CG, Lin FJ, Chen YC, Lin YK, Lu YY, Higa S, et al. 3-Hydroxybutyrate Prevents Pulmonary Vein Arrhythmogenesis by Regulating Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Oxidative Stress. Pharmacology. 2026:1-16. doi:10.1159/000551614
BibTeX
@article{Chin2026,
author = {Chin, Chye-Gen and Lin, Fong-Jhih and Chen, Yao-Chang and Lin, Yung-Kuo and Lu, Yen-Yu and Higa, Satoshi and Kao, Yu-Hsun and Chen, Shih-Ann and Chen, Yi-Jen},
title = {3-Hydroxybutyrate Prevents Pulmonary Vein Arrhythmogenesis by Regulating Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Oxidative Stress},
journal = {Pharmacology},
year = {2026},
pages = {1--16},
doi = {10.1159/000551614}
}
EUVIMED